Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

NCT07344818 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07344818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07344818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
Lead sponsor
Peking University People's Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
January 7, 2026
Completion date
May 31, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

r/r aggressive b-cell lymphoma